Screener
Kura Oncology KURA EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Kura Oncology’s reported figures.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
FAQ
- What is Kura Oncology's EBIT?
- Kura Oncology (KURA) reported EBIT of -$78.82M in Q1 2026.
- How has Kura Oncology's EBIT changed year-over-year?
- Kura Oncology's EBIT decreased by 21.8% year-over-year, from -$64.7M to -$78.82M.
- What is the long-term trend for Kura Oncology's EBIT?
- Over 3 years (2022 to 2025), Kura Oncology's EBIT has grown at a 29.5% compound annual growth rate (CAGR), from -$139.87M to -$303.63M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Kura Oncology's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude